Levobupivacaína Normon (Levobupivacaine)

Levobupivacaine works by reversibly inhibiting voltage‑gated sodium channels on neuronal membranes. This blockade prevents the initiation and propagation of action potentials, thereby stopping the transmission of pain signals and producing a reversible loss of sensation in the area where it is administered.

The specific dose of Levobupivacaína Normon is determined by the prescribing clinician based on the type of procedure, patient characteristics, and route of administration. Healthcare professionals calculate the appropriate amount according to established clinical guidelines and individual patient needs.

Safety data for levobupivacaine in pregnancy are limited, and the drug is classified as pregnancy category unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding considerations should be discussed with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and offers a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. Both agents block sodium channels, but levobupivacaine’s stereochemistry provides an improved safety margin, making it a preferred choice in many clinical settings.

Levobupivácina Normon should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light and moisture. Do not freeze. Inspect the container for any particulate matter or discoloration before use, and follow aseptic techniques during preparation.

The product is supplied as a sterile solution for injection and is administered by a qualified healthcare professional via epidural, infiltration, or intrathecal routes. The specific technique, volume, and concentration are selected based on the clinical indication and patient factors, following standard anesthetic practice.

Serious risks include cardiac arrhythmias, severe hypotension, central nervous system toxicity such as seizures, and rare allergic reactions (anaphylaxis). Early signs of toxicity—such as tinnitus, metallic taste, or circumoral numbness—should prompt immediate evaluation and supportive measures.

Patients with a known hypersensitivity to levobupivacaine or other amide‑type local anesthetics should not receive the product. It is also contraindicated in individuals with severe cardiac conduction disorders, uncontrolled epilepsy, or those in whom the risk of local anesthetic systemic toxicity cannot be adequately managed.